BMEA biomeafusion.com Earnings growth forecast for next year
The forward EPS dynamics model for Biomea Fusion, Inc. (BMEA) on GURU.Markets captures the current trend, with the indicator standing at -11.70. BMEA share price growth is being driven by BMF-219 trials for pancreatic regeneration. Unique patents and strict FDA oversight serve as a moat for the business. Environmental policy is based on the safe disposal of laboratory waste and "green office" principles.
BMEA (Biomea Fusion Inc): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- market capitalization data:
- book capitalization indicators:
- debt and solvency information:
Total Debt to Capital Biomea Fusion, Inc.|BMEA - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Biomea Fusion Corp|BMEA - Company Total Debt Obligations|Debt to Book Capitalization Ratio Biomea|BMEA - Company Long-Term Liabilities|Company Short-Term Debts Biomea Fusion|Quick Ratio biomeafusion.com
- net income and valuation ratios data:
BMEA - Net Financial Result|Expected Profit Biomea Fusion, Inc.|BMEA - Market Cap to Earnings|Future Price to Earnings Biomea Fusion Inc|BMEA - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Biomea Fusion|BMEA - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Biomea Fusion|BMEA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months biomeafusion.com|BMEA - Earnings per share increase in current year|Earnings growth forecast for next year Biomea Fusion, Inc.
- total revenue and sales volume data:
Initial company analysis:BMEA, biomeafusion.com
Market expectations for Biomea Fusion, Inc. (BMEA) often outpace the biotech's actual stage of development. This EPS growth forecasting model for the coming year visualizes consolidated analyst estimates for earnings per share. This indicator's trend reflects the market's confidence in the commercial success of the drugs. However, a high dependency on third-party CRO/CMOs leaves these forecasts vulnerable to any disruptions in the outsourcing chain.
Analysis of competing companies
ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (Rhythm Pharma)|Net earnings per share growth forecast for next year akerotx.com AKRO|Metsera Therapeutics (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|CRNX: Net earnings per share growth forecast for next year|NAMS: Earnings growth forecast for next year|SLNO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Amicus Corp|89bio Pharma (ETNB) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year agios.com (AGIO)|Expected earnings per share growth for next year structuretx.com GPCR|Net earnings per share growth forecast for next year MiMedx Group Inc MDXG|Expected earnings per share trend next year RZLT|lexpharma.com - Earnings growth forecast for next year|MBX (MBX Biosciences Inc) - Projected earnings per share growth rate for next year|ALT: Earnings growth forecast for next year|Aardvark Therapeutics Inc - Expected earnings per share trend next year|SGMT (Sagimet Biosciences, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year BioAge|Earnings growth forecast for next year QNCX|Projected earnings per share increase next year GUTS|Earnings growth forecast for next year VTVT (vTv Therapeutics Inc.)|Expected earnings per share trend next year ATPC|Pluristem Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year synlogictx.com SYBX|LPCN: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year
